Since VEGF has emerged as a potential component in the pathophysiology of stress and stress-related disorders, animal and clinical studies have attempted to delineate its precise role.
Recently, with rapidly growing knowledge about the neurobiology and genetics of psychiatric disorders, animal models of these diseases are gaining popularity in psychiatric research.
Bob's impact on the field of Behavioral Neuroscience includes the behavior, neurocircuitry, neurochemistry, and pharmacology related to social interactions, aggressive behavior, defensive behaviors, flight, freezing, threat, attack, risk assessment, anxiety disorders, animal models, models of social behavior, and autism.
To identify potential toxicities, we consulted the existing evidence from AAV gene therapy for other nervous system disorders (animal toxicology and human studies) and from the clinical pharmacology of conventional analgesic drugs.
In order to study its implications in this disorder, animal models have been used.
In order to develop new antiepileptics and understand the pathogenetic mechanisms underlying seizure disorders, animal models of epilepsy are invaluable.
Although a primate model (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, also known as MPTP) has been useful for defining a stimulation site in Parkinson's disorder, animal models have generally been of limited value in psychiatry.
176 Concerning cognitive disorders, animal studies showed that restoring IGF-1 levels in transgenic mice with Alzheimer's disease decreased αβ-amyloid accumulation, a hallmark neuropathological lesion of Alzheimer's disease.
Translational approaches to modeling affective disorders in animals will ultimately provide novel treatments and a better understanding of the neurobiological underpinnings behind these debilitating disorders.
To model a psychiatric disorder in animals: schizophrenia as a reality test.
Lipska, B. K. & Weinberger, D. R. To model a psychiatric disorder in animals: schizophrenia as a reality test.
